Document Detail


20th-century advances in drug therapy in oncology--Part. II.
MedLine Citation:
PMID:  11028247     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ongoing research in cancer therapy has led to the development of antineoplastic agents which target specific components of the cell cycle. In Part II of this series, we discuss agents which target the mitotic mechanism by inhibiting microtubules. Although many of these agents are being shown to have multiple effects, the Vinca alkaloids and the taxanes are known as antimitotic drugs. They are among the most important anticancer agents currently available, and because of their unique mechanisms, can be combined with a wide variety of other antineoplastic agents in a spectrum of diseases. In addition, in part II, we are discussing agents that target DNA and prevent replication and thus cell growth by inhibiting the enzymes which protect DNA during replication, the topoisomerases. These drugs, too, have unique mechanisms of action and have become major components of combination regimens. The topoisomerase I inhibitors are new drugs derived from an older parent drug, and their full possibilities are still being explored.
Authors:
J P Dutcher; Y Novik; K O'Boyle; G Marcoullis; C Secco; P H Wiernik
Related Documents :
11672877 - Drug targeting to choroidal neovascularization.
19451287 - Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
9416967 - New horizons in the treatment of tuberculosis.
18387177 - Killing cancer cells by targeted drug-carrying phage nanomedicines.
12869837 - Stability of adherence to highly active antiretroviral therapy over time among clients ...
24101367 - Approaches for drug delivery with intracortical probes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  40     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2001-01-16     Completed Date:  2001-02-01     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1079-92     Citation Subset:  IM    
Affiliation:
Our Lady of Mercy Cancer Center, New York Medical College, Bronx 10466, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / adverse effects,  therapeutic use*
Bridged Compounds / therapeutic use
Camptothecin / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
DNA Topoisomerases, Type I / antagonists & inhibitors
Drug Therapy / trends
Humans
Neoplasms / drug therapy*
Podophyllotoxin / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use
Taxoids*
Vinca Alkaloids / adverse effects,  therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Bridged Compounds; 0/Taxoids; 0/Vinca Alkaloids; 1605-68-1/taxane; 518-28-5/Podophyllotoxin; 7689-03-4/Camptothecin; EC 5.99.1.2/DNA Topoisomerases, Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  From symbols to flesh: the polymorphous destiny of narration.
Next Document:  Adverse drug reactions: a review of relevant factors.